orlynvah
orlynvah: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Iterum Therapeutics plc (ITRM) | Approved |
FDA Decisions
Frequently asked questions
Who is developing orlynvah?
orlynvah is being developed by Iterum Therapeutics plc.
What is orlynvah's latest FDA decision?
The most recent tracked FDA decision for orlynvah is Approval for 1 INDICATIONS AND USAGE ORLYNVAH, a combination of sulopenem etzadroxil, a penem antibacterial, and probenecid, a renal tubular transport inhibitor, is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. ( 1.1 ) Limitations of Use ORLYNVAH is not indicated for the treatment of: Compli, dated October 25, 2024.
Get deeper analysis on orlynvah
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis